guideline-directed therapy-St. Antonius Hospital-atrial fibrillation-atrial flutter

This refers to the guideline-directed antithrombotic therapy regimen used as the reference arm in the WOEST 3 clinical trial, sponsored by St. Antonius Hospital. The regimen consists of the direct oral anticoagulant (DOAC) edoxaban combined with a P2Y12 inhibitor (such as clopidogrel), with aspirin typically limited to the peri-procedural period or up to 30 days in high-risk cases. This triple or dual antithrombotic strategy is designed to prevent both stroke (via edoxaban) and stent thrombosis or myocardial infarction (via antiplatelet agents) in patients with atrial fibrillation or atrial flutter who undergo percutaneous coronary intervention (PCI). The regimen follows current European Society of Cardiology (ESC) guidelines for the management of patients with atrial fibrillation and acute coronary syndrome or PCI.

Other names

edoxaban + P2Y12 inhibitor + aspirinGuideline-directed therapy (WOEST 3)GDT (WOEST 3)